Revolution Medicines, Inc. Common Stock RVMD
i
Market dataready · fetched 2026-11-13T01:28:07.410Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T23:02:48.107579421Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T01:21:09.981873+00:00
Revolution Medicines, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 194.45 | 66.2% | 10.3% | 165.04 | 65.1% | 8.4% |
| 25Δ | 190.96 | 64.5% | 8.6% | 168.21 | 60.6% | 6.9% |
| 30Δ | 187.72 | 60.9% | 7.1% | 170.88 | 58.3% | 5.7% |
| 35Δ | 184.73 | 57.1% | 5.7% | 172.89 | 58.9% | 5.1% |
| 40Δ | 182.72 | 56.9% | 5.0% | 174.90 | 59.5% | 4.4% |
| 45Δ | 180.71 | 56.7% | 4.2% | 176.97 | 61.8% | 3.9% |
| 50Δ | 178.80 | 56.1% | 3.6% | 179.04 | 64.1% | 3.5% |
| 55Δ | 176.96 | 55.4% | 3.1% | 181.30 | 66.0% | 3.1% |
| 60Δ | 175.11 | 54.6% | 2.5% | 183.73 | 67.6% | 2.6% |
| 65Δ | 173.24 | 54.2% | 2.1% | 186.46 | 69.6% | 2.2% |
| 70Δ | 171.36 | 53.8% | 1.7% | 189.52 | 72.0% | 1.8% |
| 75Δ | 169.49 | 52.8% | 1.3% | 193.30 | 74.9% | 1.5% |
| 80Δ | 167.66 | 50.4% | 1.0% | 198.72 | 81.5% | 1.2% |
20Δ
- Pseudo strike
- 194.45
- IV
- 66.2%
- B/E move
- 10.3%
- Pseudo strike
- 165.04
- IV
- 65.1%
- B/E move
- 8.4%
25Δ
- Pseudo strike
- 190.96
- IV
- 64.5%
- B/E move
- 8.6%
- Pseudo strike
- 168.21
- IV
- 60.6%
- B/E move
- 6.9%
30Δ
- Pseudo strike
- 187.72
- IV
- 60.9%
- B/E move
- 7.1%
- Pseudo strike
- 170.88
- IV
- 58.3%
- B/E move
- 5.7%
35Δ
- Pseudo strike
- 184.73
- IV
- 57.1%
- B/E move
- 5.7%
- Pseudo strike
- 172.89
- IV
- 58.9%
- B/E move
- 5.1%
40Δ
- Pseudo strike
- 182.72
- IV
- 56.9%
- B/E move
- 5.0%
- Pseudo strike
- 174.90
- IV
- 59.5%
- B/E move
- 4.4%
45Δ
- Pseudo strike
- 180.71
- IV
- 56.7%
- B/E move
- 4.2%
- Pseudo strike
- 176.97
- IV
- 61.8%
- B/E move
- 3.9%
50Δ
- Pseudo strike
- 178.80
- IV
- 56.1%
- B/E move
- 3.6%
- Pseudo strike
- 179.04
- IV
- 64.1%
- B/E move
- 3.5%
55Δ
- Pseudo strike
- 176.96
- IV
- 55.4%
- B/E move
- 3.1%
- Pseudo strike
- 181.30
- IV
- 66.0%
- B/E move
- 3.1%
60Δ
- Pseudo strike
- 175.11
- IV
- 54.6%
- B/E move
- 2.5%
- Pseudo strike
- 183.73
- IV
- 67.6%
- B/E move
- 2.6%
65Δ
- Pseudo strike
- 173.24
- IV
- 54.2%
- B/E move
- 2.1%
- Pseudo strike
- 186.46
- IV
- 69.6%
- B/E move
- 2.2%
70Δ
- Pseudo strike
- 171.36
- IV
- 53.8%
- B/E move
- 1.7%
- Pseudo strike
- 189.52
- IV
- 72.0%
- B/E move
- 1.8%
75Δ
- Pseudo strike
- 169.49
- IV
- 52.8%
- B/E move
- 1.3%
- Pseudo strike
- 193.30
- IV
- 74.9%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 167.66
- IV
- 50.4%
- B/E move
- 1.0%
- Pseudo strike
- 198.72
- IV
- 81.5%
- B/E move
- 1.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 51.48% | |
| 53.71% | |
| 52.14% | |
| 53.79% | |
| 55.85% | |
| 50.79% | |
| 48.79% | |
| 49.64% | |
| 49.19% | |
| 48.38% | |
| 49.98% | |
| 49.66% | |
| 48.40% | |
| 48.12% | |
| 48.63% | |
| 48.67% | |
| 50.08% | |
| 49.72% | |
| 48.52% | |
| 47.18% | |
| 49.69% | |
| 49.63% | |
| 49.78% | |
| 52.51% | |
| 46.59% | |
| 47.05% | |
| 46.65% | |
| 46.35% | |
| 46.97% | |
| 47.40% | |
| 48.77% | |
| 48.30% | |
| 48.13% | |
| 46.75% | |
| 47.31% | |
| 46.50% | |
| 45.62% | |
| 46.16% | |
| 52.77% | |
| 49.94% | |
| 51.52% | |
| 55.25% | |
| 54.35% | |
| 56.13% | |
| 54.42% | |
| 53.39% | |
| 55.46% | |
| 55.14% | |
| 56.85% | |
| 56.66% | |
| 57.99% | |
| 57.02% | |
| 55.92% | |
| 55.86% | |
| 57.05% |
Biotechnology
RXRX
Description unavailable
More →RYTM
Description unavailable
More →RZLT
Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. The company is headquartered in Redwood City,…
More →SABS
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in…
More →SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
More →SEPN
Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform. The company combines…
More →